CloneID: H5.3
Antigen Long Description: H5.3 was generated from hybridomas created by fusing PBMCs (peripheral blood mononuclear cells) from human donors who had been previously received an A/Vietnam/1203/2004 H5N1 subunit vaccine with myeloma cells. The hybridoma cells were screened for those showing binding affinity for H5 HA.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG format, for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q5EP31
Specificity Statement: H5.3 binds to H5 at the head domain at an epitope which involves the 190 loop. The epitope was determined to be LGVSSA (aa 134-139) and YQGKSS (aa 142-147) of the head domain by DXMS (deuterium exchange mass spectrometry). This antibody shows reactivity with the wild-type H5N1 field strains VN/1203 (EC50 ~ 17 ng/ml), HK/156 (EC50 ~ 18 ng/ml), Anhui (EC50 ~ 2.8 ug/ml) and Indo (EC50 ~ 10 ug/ml). HA is a viral glycoprotein initially assembled as a trimer on the viral envelope as the preprotein HA0. It is subsequently cleaved by host proteases.
Application Notes (Clone): H5.3 binds to H5 where it is able to block the receptor binding site on HA by inserting its CDR3 into the site (IC50 ~ 20 ng/ml). H5.3 can neutralize wild-type VN/1203, rdt VN/1203 K and VN/1203 F pseudovirions, all with IC50s of 5 ng/ml. This antibody also has potent HI (hemagglutination inhibition) activity (80 ng/ml).